TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age; greater than 12 years old and able to cooperate for full study protocol~* Subject able to understand and sign informed consent~* Subject able to participate in complete ophthalmic and ocular motility evaluation~* Subjects with Infantile Nystagmus Syndrome diagnosed by clinical evaluation and eye movement recordings~* Best-binocular visual acuity in null position 20/50 to 20/200 inclusive using ATS or ETDRS vision testing~* Subject/family able and willing to make the required study visits~* No previous ophthalmic treatment for nystagmus other than for refractive error~Exclusion Criteria:~* Any current use of systemic or topical medications (traditional or non-traditional)~* History of ocular surgery, trauma or chronic ocular disease other than amblyopia~* Systemic diseases requiring medication or other treatments that are known to affect the ocular motor system (e.g., depression, seizure disorders, psychosis)~* Behavioral or neurological disorders which interfere with the study~* Physical or mental impairment precluding study compliance~* Participation in any study involving an IND investigational drug within the past year~* Individual (female) is pregnant, nursing or planning a pregnancy (The safety of Azopt for use during pregnancy has NOT been determined.)~* Periodicity or aperiodicity of INS present on eye movement recordings~* Allergy to sulfa or other components of Azopt solution

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Brinzolamide (Azopt) (Type: ACTIVE_COMPARATOR): ophthalmic drop given three times a day
- placebo ophthalmic drop in 5 mL solution (Type: PLACEBO_COMPARATOR): masked non-active eye drop (absence of Brinzolamide)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate~Exclusion Criteria:~* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): None
- Sequence 2 (Type: EXPERIMENTAL): None
- Sequence 3 (Type: PLACEBO_COMPARATOR): None
- Sequence 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine Modulation of The Brain's Pain Matrix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated Written informed consent~2. Age between 20 and 65.~3. Caucasian~4. That it is in the researcher's belief that the subject fully understand the contents of the study and is willing and able to comply with instructions, have the opportunity to meet with visitors, and is expected to complete the entire study. Further, it is in the researcher's beliefs (by which demanded strict action to exclusion criterion 4 and 5) that subjects with abusive tendencies are not included .~5. The person must be healthy ie. without previous chronic or recurrent pain rewarding diseases. Including the person must have:~   1. a blood pressure is 140/90 or less. If not satisfied, a medical assessment to determine whether the person is still included, albeit with a comment and reasons recorded in the CRF.~  2. a resting heart rate of at least 45 bpm. minute (measured after 5 minutes of recumbent rest). If not satisfied, a medical assessment to determine whether the person is still included, albeit with a comment and reasons recorded in the CRF.~6. That women use safe contraceptive methods as the pill, coil, depot injection of progestin subdermal implantation, hormonal vaginal ring and transdermal patch.~7. Negative pregnancy test prior to the conclusion of the experiment~Exclusion Criteria:~1. Pregnancy.~2. Known allergy to study medication~3. Current or previous participation in another drug trial within 30 days before screening.~4. Former participation in trials when given morphine or morphine-like substances.~5. Former addiction behaviors defined as abuse of alcohol, marijuana, opiates or other narcotics or family members who have been / are a drug addict.~6. Earlier pain rewarding or mental illness.~7. Expected need for medical treatment, surgery or hospitalization during the study~8. Concomitant use of strong pain medications~9. Use of any analgesics 24 hours before each test.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Morphine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Exclusion Criteria:~1. TTP, (defined as ADAMTS-13 activity \<5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory~2. Malignancy within 5 years of screening~3. Typical HUS (Shiga toxin +)~4. Known HIV infection~5. Identified drug exposure-related HUS.~6. Infection-related HUS~7. HUS related to bone marrow transplant~8. HUS related to vitamin B12 deficiency~9. Renal function status requiring chronic dialysis~10. Patients with a confirmed diagnosis of sepsis~11. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease~12. Pregnancy or lactation~13. Unresolved meningococcal disease~14. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome~15. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study~16. Patients who have received previous treatment with eculizumab~17. Patients receiving IVIG within 8 weeks or Rituximab therapy within 12 weeks of screening.~18. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or tacrolimus are excluded unless: \[1\] part of an established post-transplant anti-rejection regime, \[2\] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and \[3\] dose of such medications have been unchanged for at least 4 weeks prior to the screening period or \[4\] patient is experiencing an acute aHUS relapse immediately after transplant~19. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period, or a washout period of at least 2 weeks from the last dose of ESA therapy.~20. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.~21. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented urothelial carcinoma (squamous differentiation or mixed cell types allowed).~* Metastatic disease or locally advanced disease that is not resectable.~* Must have received prior treatment with a CPI in the locally advanced or metastatic urothelial cancer setting. A CPI is defined as a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Patients who received CPI therapy in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or within 3 months of therapy completion are eligible.~* Must either have prior treatment with platinum-containing chemotherapy (Cohort 1) or be platinum-naïve and ineligible for treatment with cisplatin at time of enrollment (Cohort 2).~* Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.~* Tumor tissue samples must be available for submission to the sponsor prior to study treatment.~* Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).~* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1 for Cohort 1 or ≤2 for Cohort 2.~* Anticipated life expectancy of ≥3 months as assessed by the investigator.~Exclusion Criteria:~* Ongoing sensory or motor neuropathy Grade ≥2.~* Active central nervous system (CNS) metastases.~* Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis.~* Prior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).~* Uncontrolled tumor-related pain or impending spinal cord compression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enfortumab vedotin (Type: EXPERIMENTAL): Enfortumab vedotin on days 1, 8 and 15 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>18 years of age~* RA for \>=6 months~* Receiving outpatient treatment~* Ongoing treatment with methotrexate for \>=3 months, stable for \>=1 month~* Inadequate response or intolerance to etanercept, infliximab or adalimumab~Exclusion Criteria:~* Previous treatment with MabThera~* Concurrent treatment with any anti TNF-alfa therapy or biologic therapy~* Previous treatment with any investigational cell-depleting therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 1000 mg IV rituximab
- B (Type: EXPERIMENTAL): 2 x 1000 mg IV rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline~Exclusion Criteria:~* Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg~* History of angioedema, drug-related or otherwise, as reported by the patient~* Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.~* Patients have significant cardiovascular co-morbidities~* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 200 mg (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
- LCZ696 400 mg (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
- LCZ696 400 mg plus other hypertension (HTN) medications (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zenith(R) Low Profile AAA Endovascular Graft Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Abdominal aortic, aortoiliac, and iliac aneurysms of appropriate size~* Vessels suitable for endovascular access and aneurysm repair~Exclusion Criteria:~* Less than 18 years of age~* Inability or refusal to give informed consent~* Disease considerations that would compromise patient safety or study outcomes~* Unsuitable arterial anatomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Treatment with Endovascular Graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria~* Participants resistant to or intolerant of hydroxyurea~* Participants with a phlebotomy requirement~* Participants with splenomegaly (palpable or non-palpable) and a spleen volume, as measured by MRI (or CT in applicable participants ), of greater than or equal to 450 cubic centimeters~* Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Exclusion Criteria:~* Women who are pregnant or nursing~* Participants with inadequate liver or renal function~* Participants with significant bacterial, fungal, parasitic, or viral infection requiring treatment~* Participants with an active malignancy within the past 5 years, excluding specific skin cancers~* Participants with known active hepatitis or HIV positivity~* Participants who have previously received treatment with a JAK inhibitor~* Participants being treated with any investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ruxolitinib tablets (Type: EXPERIMENTAL): Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
- Best Available Therapy (Type: OTHER): Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Oxybate in Schizophrenia With Insomnia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-45 with a DSM-IV diagnosis of schizophrenia and insomnia related to schizophrenia, confirmed by a structured interview (SCID).~Exclusion Criteria:~* Lack of capacity to give informed consent (capacity is determined by a licensed member of the treatment team).~* Unstable medical illness.~* Diagnosis of restless leg syndrome, a seizure disorder, uncontrolled hypertension, unstable cardiac illness, or obstructive sleep apnea.~* Pregnancy or lack of adequate birth control.~* History of substance dependence disorder.~* Current treatment with valproic acid.~* Succinic semialdehyde dehydrogenase deficiency (SSADH).~* Persistent need for treatment with benzodiazepines, barbiturates, opiates or other sedative hypnotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sodium oxybate (Type: EXPERIMENTAL): Active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History or laboratory evidence of herpes simplex infection~* Clinical evidence or suspicion of herpes simplex infection~Exclusion Criteria:~* Patients unable to swallow~* Concomitant use of probenecid~* Positive pregnancy test~Additional protocol-defined inclusion/exclusion criteria may apply. For detailed information on eligibility, please contact the study center nearest to you or call the following numbers: 1-862-778-3544 or 1-434-951-3228

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Famciclovir, pediatric oral formulation (Type: EXPERIMENTAL): single-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a history of SAR symptoms~* A positive skin prick test at least one grass allergen~* Moderate - severe SAR symptoms at baseline~* Women of childbearing potential must use a medically acceptable form of contraception~* 80% compliance on run in study medication and 80% compliance on completing the diary~Exclusion Criteria:~* The presence of any clinically significant comorbid disease which may interfere with the study assessments~* The presence of renal disease~* Pregnant or breastfeeding~* Subject is currently participating in another clinical trial~* Known hypersensitivity to piperazines or any of the excipients~* Intake of medications prohibited before the start of the trial~* Subjects who started or changed the dose of immunotherapy~* Rhinitis medicamentosa~* Subjects with a recent history (within the last 2 years) of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo tablets
- LCTZ (Type: EXPERIMENTAL): 5 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete